Discover
OTLK
Outlook Therapeutics, Inc.
1.47
37 x 1.43
2 x 1.81
bid
ask
-
0.12
7.55%
20 @ 07:11 AM
1.49 +0.02 (1.36%)
| Ytd | -6.96% | |
| 1y | -6.96% |
1.42
day range
1.57
0.16
52 week range
3.39
| Open | 1.55 | Prev Close | 1.59 | Low | 1.42 | High | 1.57 | Mkt Cap | 218.42M |
| Vol | 8.77M | Avg Vol | 18.92M | EPS | -1.13 | P/E | N/A | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.73 | 200-d Avg | 0.90 | 1yr Est | 24.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-27 | 2024-09 | -0.83 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -1.06 | -0.83 | 0.23 | 21.70% |
| 2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
| 2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
| 2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
| 2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-02 | Chardan Capital | Downgrade | Buy | Neutral |
| 2024-11-29 | BTIG | Upgrade | Buy | Buy |
| 2024-11-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-16 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
| 2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
| 2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
| 2024-09-25 | KENYON LAWRENCE A. | Chief Financial Officer | 5.95K | Purchase |
| 2024-03-17 | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2024-04-14 | SYNTONE VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 1.71M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Tang Capital Management, LLC | 1.56M | 2.21M | 6.59% |
| 2024-09-29 | Great Point Partners LLC | 1.29M | 1.84M | 5.47% |
| 2024-09-29 | Blackrock Inc. | 1.04M | 1.48M | 4.42% |
| 2024-09-29 | Vanguard Group Inc | 855.88K | 1.22M | 3.62% |
| 2024-09-29 | Altium Capital Management, LP | 541.55K | 769.00K | 2.29% |
| 2024-09-29 | Rosalind Advisors, Inc. | 450.00K | 639.00K | 1.90% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 442.51K | 628.37K | 1.87% |
| 2024-10-30 | iShares Russell 2000 ETF | 369.41K | 524.57K | 1.56% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 281.28K | 399.42K | 1.19% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 103.67K | 147.21K | 0.44% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 82.27K | 116.82K | 0.35% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 79.46K | 112.84K | 0.34% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2024-03-14 |
| 1 : 8 | 2019-03-18 |